Larimar Therapeutics Total Assets 2011-2026 | LRMR

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.

Main categories of assets
Current assets (used within one year):

Cash and cash equivalents
Accounts receivable (amounts owed by customers)
Inventory of goods, raw materials, and supplies
Short-term investments

Non-current assets (used for more than one year):

Fixed assets (buildings, machinery, equipment)
Intangible assets (brands, patents, software)
Long-term investments
Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets Larimar Therapeutics

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
146 M	200 M	95.9 M	126 M	78.7 M	105 M	80.7 M	122 M	106 M	132 M	189 M	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
200 M	78.7 M	125 M

Quarterly Total Assets Larimar Therapeutics

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
187 M	150 M	170 M	200 M	219 M	237 M	248 M	95.9 M	104 M	112 M	119 M	126 M	133 M	62.9 M	71.2 M	78.7 M	87.9 M	80.9 M	93 M	105 M	105 M	105 M	105 M	5.2 M	5.2 M	5.2 M	80.7 M	122 M	122 M	122 M	122 M	106 M	106 M	106 M	106 M	132 M	132 M	132 M	132 M	189 M	189 M	189 M	189 M	118 M	118 M	118 M	118 M	38.1 M	38.1 M	38.1 M	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
248 M	5.2 M	117 M

Total Assets of other stocks in the Biotechnology industry

Issuer	Total Assets	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	2.03 B	-	2.43 %	$ 254 M	Germany
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Adverum Biotechnologies ADVM	180 M	-	-	$ 86.2 M	USA
AlloVir ALVR	122 M	-	4.14 %	$ 49.1 M	USA
Amgen AMGN	90.6 B	$ 340.0	-0.75 %	$ 183 B	USA
Amneal Pharmaceuticals AMRX	3.68 B	$ 12.32	-0.24 %	$ 3.86 B	USA
Applied Molecular Transport AMTI	107 M	-	-	$ 10.1 M	USA
Applied Therapeutics APLT	54.8 M	-	-	$ 8.42 M	USA
I-Mab IMAB	6.33 B	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	18.1 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	151 M	-	2.54 %	$ 160 B	France
Arcutis Biotherapeutics ARQT	433 M	$ 23.27	-1.63 %	$ 2.96 B	USA
Biophytis SA BPTS	12 M	-	-13.47 %	$ 169 M	France
Autolus Therapeutics plc AUTL	589 M	$ 1.36	-2.16 %	$ 362 M	Britain
AVROBIO AVRO	101 M	-	1083.1 %	$ 745 M	USA
Ayala Pharmaceuticals AYLA	7.77 M	-	-	$ 7.46 M	Israel
AstraZeneca PLC AZN	114 B	-	-	$ 96.9 B	Britain
Midatech Pharma plc MTP	14.8 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	15.2 M	-	-1.52 %	$ 24.7 M	USA
BeiGene, Ltd. BGNE	8.19 B	-	0.49 %	$ 251 B	Cayman-islands
Alterity Therapeutics Limited ATHE	41.4 M	$ 3.76	4.35 %	$ 9.05 B	Australia
CymaBay Therapeutics CBAY	435 M	-	-	$ 3.45 B	USA
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
Aytu BioScience AYTU	124 M	$ 2.57	-3.38 %	$ 16.1 M	USA
Avid Bioservices CDMO	337 M	-	-	$ 789 M	USA
Cidara Therapeutics CDTX	215 M	-	-	$ 1.41 B	USA
Институт стволовых клеток человека ISKJ	1.51 B	-	-	-	Russia
Checkpoint Therapeutics CKPT	7.47 M	-	-	$ 169 M	USA
Cellectar Biosciences CLRB	15 M	$ 2.75	1.48 %	$ 7.17 M	USA
Aeterna Zentaris AEZS	35.1 M	-	5.93 %	$ 314 M	Canada
Checkmate Pharmaceuticals CMPI	78.8 M	-	-	$ 231 M	USA
AgeX Therapeutics AGE	6.95 M	-	-10.17 %	$ 12.2 K	USA
Concert Pharmaceuticals CNCE	165 M	-	-	$ 401 M	USA
Aeglea BioTherapeutics AGLE	778 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	66.7 M	-	-	$ 26.5 M	USA
CTI BioPharma Corp. CTIC	126 M	-	-	$ 1.2 B	USA
AIkido Pharma AIKI	113 M	-	1.93 %	$ 17.4 M	USA
Aptose Biosciences APTO	10 M	-	-45.71 %	$ 1.2 M	Canada
Cyclacel Pharmaceuticals CYCCP	8.18 M	-	-4.36 %	$ 27 M	USA
Cyclerion Therapeutics CYCN	9.58 M	$ 3.48	-16.14 %	$ 8.76 M	USA
Deciphera Pharmaceuticals DCPH	474 M	-	-	$ 2.18 B	USA
Akero Therapeutics AKRO	826 M	-	-	$ 3.67 B	USA
Dynavax Technologies Corporation DVAX	986 M	-	-	$ 2.02 B	USA
CureVac N.V. CVAC	1.16 B	-	-	$ 867 M	Germany
Dyadic International DYAI	9.95 M	$ 0.88	1.66 %	$ 31.8 M	USA
BioNTech SE BNTX	22 B	$ 89.62	-1.82 %	$ 27.2 B	Germany
Coherus BioSciences CHRS	258 M	$ 1.67	-	$ 196 M	USA
Akari Therapeutics, Plc AKTX	47.9 M	$ 3.8	7.34 %	$ 256 B	Britain
Akouos AKUS	279 M	-	0.23 %	$ 488 M	USA
Allakos ALLK	244 M	-	-	$ 28.6 M	USA